Lextrading

Looking for the bounce to $20+ after the secondary offering

Long
NASDAQ:AVRO   AVROBIO, Inc
More positive clinical validates their platform. Assets further de-risked.
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.